Nyxoah S.A. is a medical technology company that focuses on developing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). The company's primary product, the Genio® system, is a minimally invasive neurostimulation device designed to alleviate OSA symptoms by stimulating the hypoglossal nerve, thereby maintaining an open airway during sleep. Nyxoah prominently impacts the healthcare sector, specifically within the sleep disorder therapeutics industry, by offering a novel alternative to traditional treatments such as Continuous Positive Airway Pressure (CPAP) machines. Based in Belgium, Nyxoah serves global markets with a commitment to improving patient outcomes through cutting-edge medical technology. As a pivotal player in the medical device sector, Nyxoah contributes to the ongoing advancements in personalized healthcare solutions, addressing a significant and underserved need in the management of sleep disorders.